Aileron Therapeutics Files Routine 8-K on Jan 25, 2024

TL;DR

**Aileron Therapeutics filed a routine 8-K, no major news.**

AI Summary

Aileron Therapeutics, Inc. filed an 8-K on January 25, 2024, to report an "Other Event" and provide "Financial Statements and Exhibits." This filing indicates that the company is fulfilling its reporting obligations under the Securities Exchange Act of 1934. For investors, this filing primarily serves as a routine update, confirming the company's compliance with SEC regulations and providing basic corporate information, rather than announcing a significant new development.

Why It Matters

This filing is a standard compliance update, indicating Aileron Therapeutics is meeting its regulatory obligations. It doesn't contain new material information that would immediately impact stock price.

Risk Assessment

Risk Level: low — This 8-K is a standard regulatory filing and does not disclose any new risks or significant events.

Analyst Insight

This filing is routine and does not provide new information to warrant immediate investment action. Investors should continue to monitor for more substantive announcements, such as clinical trial results or financial earnings.

Key Numbers

• 001-38130 — Commission File Number (identifies Aileron Therapeutics' registration with the SEC)
• 13-4196017 — IRS Employer Identification No. (identifies Aileron Therapeutics for tax purposes)
• (617) 995-0900 — Business Phone Number (contact information for Aileron Therapeutics)
• 02451 — Zip Code (part of Aileron Therapeutics' principal executive offices address)

Key Players & Entities

• Aileron Therapeutics, Inc. (company) — the registrant filing the 8-K
• January 25, 2024 (date) — date of earliest event reported and filing date
• Delaware (company) — state of incorporation for Aileron Therapeutics, Inc.
• 001-38130 (other) — Commission File Number for Aileron Therapeutics, Inc.
• ALRN (other) — trading symbol for Aileron Therapeutics, Inc.

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share ALRN The Nasdaq
• $18.4 m — gregate purchase price of approximately $18.4 million, which included the conversion of
• $1.6 million — egate principal amount of approximately $1.6 million issued by Lung to Bios Partners prior t
• $19.9 million — November 30, 2023, we had approximately $19.9 million in cash and cash equivalents. Based on

Filing Documents

• d154367d8k.htm (8-K) — 663KB
• d154367dex101.htm (EX-10.1) — 319KB
• d154367dex102.htm (EX-10.2) — 169KB
• d154367dex103.htm (EX-10.3) — 220KB
• d154367dex104.htm (EX-10.4) — 92KB
• d154367dex105.htm (EX-10.5) — 84KB
• 0001193125-24-014835.txt ( ) — 1990KB
• alrn-20240125.xsd (EX-101.SCH) — 3KB
• alrn-20240125_lab.xml (EX-101.LAB) — 17KB
• alrn-20240125_pre.xml (EX-101.PRE) — 11KB
• d154367d8k_htm.xml (XML) — 3KB

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K, or the Current Report, contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Current Report, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management and expected market growth are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among other things, statements about: our plans to develop and commercialize LTI-03 and LTI-01, including the potential benefits thereof; our unproven approach to drug research and development in the area of fibrotic diseases, with a focus on Caveolin-1, or Cav1, -related peptides, and our ability to develop marketable products; our ongoing and future clinical trials for LTI-03 and LTI-01, whether conducted by us or by any future collaborators, including our ability to enroll patients in our clinical trials, the timing of initiation of these trials and of the anticipated results; the possibility that we may be adversely affected by economic, business, and/or competitive factors, including risks inherent in pharmaceutical research and development, such as: adverse results in our drug discovery, preclinical and clinical development activities, the risk that the results of our preclinical studies and early clinical trials may not be replicated in later clinical trials, and the risk that any of our clinical trials may not commence, continue or be completed on time, or at all; our ability to recognize the anticipated ben

RISK FACTORS

RISK FACTORS Risks Related to Our Business Our business is highly dependent on the success of our product candidates, LTI-03 and LTI-01 and any other product candidates that we advance into clinical development. Our approach to drug discovery and development in the area of fibrotic diseases, with a focus on Cav1-related peptides, is unproven and may not result in marketable products. All of our product candidates will require significant additional development before we may be able to seek regulatory approval for and launch a product commercially. Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to LTI-03, LTI-01, or other product candidates. We currently have no products that are approved for commercial sale and may never be able to develop marketable products. We have two clinical product candidates, LTI-03 and LTI-01, in early- and mid-stage clinical development, respectively. If either of our clinical product candidates encounter safety or efficacy problems, development delays, regulatory issues or other problems, our development plans and business would be significantly harmed. We have completed a Phase 1a safety and tolerability clinical trial of LTI-03 in healthy normal volunteers and are currently recruiting a Phase 1b dose ranging, placebo-controlled safety and tolerability trial of LTI-03 in IPF patients. We have completed a Phase 1b safety, tolerability and proof of mechanism trial and a Phase 2a dose-ranging, placebo-controlled trial of LTI-01 in loculated pleural effusion, or LPE, patients. We must successfully complete Phase 3 clinical trials prior to obtaining FDA approval of LTI-03 or LTI-01 for commercial use. For each product candidate, we must demonstrate its safety and efficacy in humans, obtain regulatory approval in one or more jurisdictions, obtain manufacturing supply, capacity and expertise, and substantially invest in marketing efforts before we are able to

View Full Filing

View this 8-K filing on SEC EDGAR